{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T20:20:11Z","timestamp":1788034811200,"version":"build-2784847793"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ejca.2018.06.010","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T13:16:37Z","timestamp":1532697397000},"page":"143-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature"],"prefix":"10.1016","volume":"101","author":[{"given":"Go","family":"Nishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2018.06.010_bib1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.cell.2016.12.015","article-title":"Implementing genome-driven oncology","volume":"168","author":"Hyman","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ejca.2018.06.010_bib2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/nrclinonc.2015.19","article-title":"Biomarkers: exceptional responders-discovering predictive biomarkers","volume":"12","author":"Takebe","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"7547","key":"10.1016\/j.ejca.2018.06.010_bib3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/520389a","article-title":"Cancer: a most exceptional response","volume":"520","author":"Marx","year":"2015","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ejca.2018.06.010_bib4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/cncr.29311","article-title":"NCI launches exceptional responders initiative: researchers will attempt to identify why some patients respond to treatment so much better than others","volume":"121","author":"Printz","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2018.06.010_bib5","series-title":"Proceedings of the 106th Annual Meeting of the American Association for Cancer Research","article-title":"The NCI exceptional responders initiatives: initial feasibility result","volume":"75","author":"Conley","year":"2015"},{"key":"10.1016\/j.ejca.2018.06.010_bib6","series-title":"Cancer researchers report progress in studying exceptional responders","year":"2017"},{"issue":"6104","key":"10.1016\/j.ejca.2018.06.010_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.1226344","article-title":"Genome sequencing identifies a basis for everolimus sensitivity","volume":"338","author":"Iyer","year":"2012","journal-title":"Science (New York, NY)."},{"issue":"12","key":"10.1016\/j.ejca.2018.06.010_bib8","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.mayocp.2015.08.017","article-title":"Characteristics of exceptional or super responders to cancer drugs","volume":"90","author":"Prasad","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"33","key":"10.1016\/j.ejca.2018.06.010_bib9","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","article-title":"Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers","volume":"28","author":"Von Hoff","year":"2010","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2018.06.010_bib10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/0284186X.2015.1096020","article-title":"Does long-term survival exist in pancreatic adenocarcinoma?","volume":"55","author":"Zijlstra","year":"2016","journal-title":"Acta Oncol (Stockholm, Sweden)."},{"issue":"9","key":"10.1016\/j.ejca.2018.06.010_bib11","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1200\/JCO.2012.47.7141","article-title":"Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene","volume":"32","author":"Chiari","year":"2014","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2018.06.010_bib12","series-title":"2016 second quarter results and recent highlights [press release]","author":"Foundation Medicine Announces","year":"2017"},{"key":"10.1016\/j.ejca.2018.06.010_bib13","article-title":"Innovations: startup's liquid biopsies match cancer patients with trials","author":"Teichert","year":"2016","journal-title":"Mod Healthc"},{"issue":"8","key":"10.1016\/j.ejca.2018.06.010_bib14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR project GENIE: powering precision medicine through an international consortium","volume":"7","author":"Consortium APG","year":"2017","journal-title":"Canc Discov"},{"issue":"22","key":"10.1016\/j.ejca.2018.06.010_bib15","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the evolution of non-small-cell lung cancer","volume":"376","author":"Jamal-Hanjani","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejca.2018.06.010_bib16","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2018.06.010_bib17","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.4389","article-title":"Functional precision cancer medicine-moving beyond pure genomics","volume":"23","author":"Letai","year":"2017","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.ejca.2018.06.010_bib18","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/nm.3915","article-title":"Toward understanding and exploiting tumor heterogeneity","volume":"21","author":"Alizadeh","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2018.06.010_bib19","series-title":"Exceptional responders initiative: questions and answers","year":"2017"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491830902X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491830902X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T19:59:35Z","timestamp":1539115175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491830902X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":19,"alternative-id":["S095980491830902X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.06.010","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}